PRGO's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 501.7 -- higher than 92.95% of US-listed equities with positive expected earnings growth.
PRGO's went public 28.88 years ago, making it older than 82.12% of listed US stocks we're tracking.
The volatility of PERRIGO Co plc's share price is greater than that of merely 6.07% US stocks with at least 200 days of trading history.
Stocks that are quantitatively similar to PRGO, based on their financial statements, market capitalization, and price volatility, are HRC, BDC, CUB, AIMC, and WAB.
PRGO's SEC filings can be seen here. And to visit PERRIGO Co plc's official web site, go to www.perrigo.com.
Perrigo Company plc Ordinary Shares (PRGO) Company Bio
Perrigo Company develops, manufactures, and distributes generic prescription pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients and pharmaceutical and medical diagnostic products. The company was founded in 1887 and is based in Dublin, Ireland.
PRGO Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for PRGO, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that PERRIGO Co plc ranked in the 35th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of PERRIGO Co plc, consider:
The stock's equity weight, or the proportion of capital from equity relative to debt, is 60. Its equity weight surpasses that of only 21.17% of free cash flow generating stocks in the Healthcare sector.
Its compound free cash flow growth rate, as measured over the past 5.5 years, is -0.07% -- higher than merely 17.15% of stocks in our DCF forecasting set.
PERRIGO Co plc's weighted average cost of capital (WACC) is 7%; for context, that number is higher than only 7.32% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
CRL, ENDP, GSK, CMD, and MOH can be thought of as valuation peers to PRGO, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
The growing demand for Topical Antibiotic Pharmaceuticals has provided a major boost to the Global Topical Antibiotic Pharmaceuticals Market as more people are shifting their preferences to this growing sector. The market is expected to keep rising at a high
A new market report by The Insight Partners on the Tinea Pedis Treatment Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis
Los Angeles, United State, – – QY Research recently added a research report, Global Actinic Keratosis Treatment Market Research Report 2020 to its ever-increasing repository. The research report discusses the future of the global Actinic Keratosis Treatment market. It highlights
Perrigo announced the voluntary nationwide recall of albuterol sulfate following complaints that some units may not dispense due to clogging. A definitive timeline for reintroduction has not been determined.